Showing 1281-1290 of 1477 results for "".
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- CSI Dry Eye Software Announces Ken Barbet as New Chief Executive Officerhttps://modernod.com/news/csi-dry-eye-software-announces-ken-barbet-as-new-chief-executive-officer/2482754/Earlier this week, CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease management, announced Ken Barbet at the company’s new Chief Executive Officer (CEO). Mr. Barbet has 30 years of executive leade
- Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trialhttps://modernod.com/news/opthea-discontinues-wet-amd-trials-after-another-failed-phase-3-trial/2482721/Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in
- China’s First IGF-1R Monoclonal Antibody Approved, Innovent Biologics Announceshttps://modernod.com/news/chinas-first-igf-1r-monoclonal-antibody-approved-innovent-biologics-announces/2482701/Innovent Biologics announced China’s approval of SYCUME® for thyroid eye disease (TED) earlier this week. SYCUME® is China’s first monoclonal antibody therapeutic option for TED and only the second available globally – marking the first new treatment
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucomahttps://modernod.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/Bausch + Lomb announced two separate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acquired Whitecap Biosciences LLC, which is developing two therapies for potential use in glaucoma and geographic atrophy (GA). Financial terms
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective